{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
PF-04479745 (PF-4479745) is a selective serotonin 5HT2C agonist. PF-4479745 displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5-HT2B in relevant tissue-based assay systems.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Org-12962 was developed by Organon as a potent and selective Serotonin 5-HT(2C) receptor agonist. It was in clinical trial phase II for depression treatment, but the investigation was discontinued. In addition, was shown, Org-12962 displayed antiaversive effects in a rat model of panic-like anxiety.
